Neurogene Inc (NASDAQ:NGNE) — Market Cap & Net Worth
Market Cap & Net Worth: Neurogene Inc (NGNE)
Neurogene Inc (NASDAQ:NGNE) has a market capitalization of $646.59 Million ($646.59 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11014 globally and #2869 in its home market, demonstrating a -14.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neurogene Inc's stock price $32.41 by its total outstanding shares 19950314 (19.95 Million). Also see balance sheet size of Neurogene Inc for a full breakdown of the balance sheet.
Neurogene Inc Market Cap History: 2015 to 2026
Neurogene Inc's market capitalization history from 2015 to 2026. Data shows change from $4.98 Billion to $646.59 Million (-18.70% CAGR). Also see Neurogene Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Neurogene Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.02% | #307 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1125 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.03% | #177 of 263 |
Weight: Neurogene Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neurogene Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neurogene Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Neurogene Inc for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
493.04x
Neurogene Inc's market cap is 493.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $861.85 Million | $25.00 Million | -$31.59 Million | 34.47x | N/A |
| 2024 | $456.06 Million | $925.00K | -$75.14 Million | 493.04x | N/A |
Competitor Companies of NGNE by Market Capitalization
Companies near Neurogene Inc in the global market cap rankings as of September 18, 2026. Review tangible equity quality of Neurogene Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Neurogene Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Neurogene Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Neurogene Inc's market cap moved from $4.98 Billion to $ 646.59 Million, with a yearly change of -18.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $646.59 Million | +57.33% |
| 2025 | $410.98 Million | -9.89% |
| 2024 | $456.06 Million | +17.96% |
| 2023 | $386.64 Million | +90.37% |
| 2022 | $203.09 Million | -89.44% |
| 2021 | $1.92 Billion | -65.82% |
| 2020 | $5.63 Billion | +14.45% |
| 2019 | $4.92 Billion | +470.37% |
| 2018 | $861.85 Million | -81.63% |
| 2017 | $4.69 Billion | -28.77% |
| 2016 | $6.59 Billion | +32.29% |
| 2015 | $4.98 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Neurogene Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $646.59 Million USD |
| MoneyControl | $646.59 Million USD |
| MarketWatch | $646.59 Million USD |
| marketcap.company | $646.59 Million USD |
| Reuters | $646.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disea… Read more